Q-omics provides the consensus-scored RPL7AP52 profile across patient tissues and cancer cell-line models. RPL7AP52 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP52 is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, RPL7AP52 RNA expression shows 5,600 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, ESCA, and STAD as cancer lineages where RPL7AP52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP52 survival associations across molecular data types. RPL7AP52 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP52 RNA expression–survival associations across cancer types. High RPL7AP52 expression shows unfavorable associations in KIRC, KIRP, THYM, UVM and LAML, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL7AP52 RNA expression.
This table summarizes RPL7AP52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP52 shows lower tumor expression in ESCA and KIRP and higher tumor expression in LUSC. The ESCA box plot shows higher RPL7AP52 RNA expression in normal versus tumor tissue (log2 FC = −0.452, t-test p = .005).
This table shows molecular features associated with RPL7AP52 in patient tissues and cancer cell lines. In patient samples, RPL7AP52 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
